JPH0793942B2 - Curing liquid for biomaterials - Google Patents
Curing liquid for biomaterialsInfo
- Publication number
- JPH0793942B2 JPH0793942B2 JP61058133A JP5813386A JPH0793942B2 JP H0793942 B2 JPH0793942 B2 JP H0793942B2 JP 61058133 A JP61058133 A JP 61058133A JP 5813386 A JP5813386 A JP 5813386A JP H0793942 B2 JPH0793942 B2 JP H0793942B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- liquid
- viscosity
- powder
- curing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims description 52
- 239000012620 biological material Substances 0.000 title claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000001506 calcium phosphate Substances 0.000 claims description 17
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 16
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 15
- 235000011010 calcium phosphates Nutrition 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 13
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001714 calcium phosphate Drugs 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 239000011575 calcium Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- -1 oxides Chemical class 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004262 dental pulp cavity Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- YDSWCNNOKPMOTP-UHFFFAOYSA-N mellitic acid Chemical compound OC(=O)C1=C(C(O)=O)C(C(O)=O)=C(C(O)=O)C(C(O)=O)=C1C(O)=O YDSWCNNOKPMOTP-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002631 root canal filling material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 2
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- RHPXYIKALIRNFA-UHFFFAOYSA-L disodium;2-[carboxylatomethyl(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CC([O-])=O RHPXYIKALIRNFA-UHFFFAOYSA-L 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 150000003388 sodium compounds Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Dental Preparations (AREA)
- Materials For Medical Uses (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は、リン酸カルシウム系生体材料用の硬化液に関
する。TECHNICAL FIELD The present invention relates to a hardening liquid for a calcium phosphate-based biomaterial.
従来の技術 リン酸カルシウム系の生体材料は、生体硬組織欠損部に
補填する生体硬組織修復材料として使われる。2. Description of the Related Art Calcium phosphate-based biomaterials are used as biohard tissue repair materials that fill in biohard tissue defects.
生体硬組織修復材料は、生体外にて目的の形状に成型加
工されたものをそのままあるいは多生の修正を施して挿
入する方法と、練成物を複雑な形状をした欠損部へ充填
し生体内にて硬化させる方法とがある。The bio-hard tissue repair material is a method of inserting the material that has been molded into the desired shape in vitro, as it is or after making a multi-faceted modification, and by filling the kneaded product into the defective portion with a complicated shape. There is a method of hardening it in the body.
いずれの場合も素材となるものは、生体との親和性、生
体に対する無刺激性および無毒性が必要で、近年生体硬
組織と類似の組成を有するリン酸カルシウム系生体材料
(セラミックス粉剤)が注目されている。In any case, the material used must be compatible with the living body, non-irritating to the living body, and nontoxic, and in recent years, calcium phosphate-based biomaterials (ceramic powders) having a composition similar to that of living hard tissues have attracted attention. There is.
この粉剤を使用に耐え得る凝結硬化体にするには、上記
のように生体外では高温高圧焼結法等が採用されるが一
般的には生体内にて直接硬化させる方法が望ましい。As described above, in order to make the powdery hardened product that can withstand use, the high temperature and high pressure sintering method and the like are employed in vitro as described above, but in general, the method of directly curing in vivo is desirable.
この場合粉剤を反応硬化させることのできる水、生理食
塩液、無機酸、有機酸、それらの塩類およびポリアクリ
ル酸系水溶液等で混練し、パテ状あるいはペースト状に
した練成物(混和泥)を患部に適応させている。In this case, the kneaded product is a putty-like or paste-like mixture (mixed mud) that is kneaded with water, a physiological saline solution, an inorganic acid, an organic acid, salts thereof and a polyacrylic acid-based aqueous solution or the like capable of reacting and curing the powder. Is adapted to the affected area.
水、生理食塩液、無機酸、一部の有機酸、易水溶性塩類
の水溶液等で混練したものは、いわゆる湿り砂状を呈
し、パサパサした取扱いにくい状態が長時間継続し、凝
結完了時間がきわめて長く粉液比も合わせにくいので実
用的でない。When kneaded with water, physiological saline solution, inorganic acid, some organic acids, aqueous solution of easily water-soluble salts, etc., it shows a so-called wet sandy state, and it remains dry and difficult to handle for a long time, and the setting completion time It is not practical because it is very long and the powder-liquid ratio is difficult to match.
一方、ポリエステル酸系の硬化液は、混練することによ
り短時間に凝固硬化し、圧縮強さも比較的高い値が出せ
る。On the other hand, the polyester acid-based curing liquid is solidified and cured in a short time by kneading, and the compression strength can be relatively high.
発明が解決しようとする問題点 しかしながら、従来のポリアクリル系硬化の場合、硬化
液の粘度(動粘度)が約1,000mm2/s以上とかなり高いた
め、混和泥の流動性が低下し操作性を重視する臨床分野
では、低粘性硬化液の出現を望んでいる。なお、本明細
書において粘度とは、液剤そのものの粘性を動粘度によ
る数値で表現したもので、液剤の流動性、取扱い易さを
示す尺度である。Problems to be Solved by the Invention However, in the case of conventional polyacrylic curing, since the viscosity (kinematic viscosity) of the curing liquid is considerably high at about 1,000 mm 2 / s or more, the fluidity of the mixed mud decreases and the operability is reduced. In the clinical field, where importance is placed on, the advent of low-viscosity hardening liquid is desired. In the present specification, the term “viscosity” represents the viscosity of the liquid agent itself by a numerical value based on the kinematic viscosity, and is a measure showing the fluidity of the liquid agent and the ease of handling.
例をあげれば、歯内療法分野では、治療により歯髄を除
去された根部歯髄腔を充填するために、リン酸カルシウ
ム系生体材料を根管充填用シーラーあるいは糊材根管充
填材として用いる。その場合は硬化液と生体材料の混和
泥の流動性が不可欠要因となり、流動性が欠如すること
により、根部歯髄腔への充填が不可能となってしまう。For example, in the endodontic field, a calcium phosphate biomaterial is used as a root canal sealer or a root canal filler in order to fill the root pulp cavity from which pulp has been removed by treatment. In that case, the fluidity of the mixed mud of the hardening liquid and the biomaterial becomes an indispensable factor, and the lack of fluidity makes it impossible to fill the root pulp cavity.
そこで、混和泥の稠度(言換れば混和泥の流動性)を臨
床操作上の好ましい値にして根部歯髄腔に混和泥を充填
しやするするには、粉剤の量をへらして粉剤/液剤(粉
液比)を大幅に下げなくてはいけない。しかし、これで
は、粉剤量が少なくなり、所望の物性ないし生体への親
和性が得られず、臨床上使用するには好ましくない。Therefore, in order to make the consistency of the mixed mud (in other words, the fluidity of the mixed mud) a preferable value for clinical operation and to fill the mixed pulp into the root pulp cavity, the amount of the powder is reduced and the powder / liquid formulation is used. (Powder / liquid ratio) must be significantly reduced. However, in this case, the amount of the powder is reduced, the desired physical properties or the affinity for the living body cannot be obtained, which is not preferable for clinical use.
他方、粘度が低すぎると、所望の圧縮強度は得られる
が、曲げ強度が不足して、もろい欠点がある。On the other hand, if the viscosity is too low, the desired compressive strength is obtained, but the bending strength is insufficient and there is a fragile defect.
発明の目的 本発明は上記の欠点を解消するためになされたものであ
り、硬化液固有の液粘性(硬化液の粘度)を下げて、混
和泥の粉液比を臨床操作上好ましい値まで上げても臨床
操作上好ましい混和泥の流動性を確保できて臨床上使用
しやすいとともに、所望の曲げ強度を得て、ねばり強い
生体材料用硬化液を提供することを目的とする。OBJECT OF THE INVENTION The present invention has been made in order to solve the above-mentioned drawbacks, and lowers the liquid viscosity specific to the curing liquid (the viscosity of the curing liquid) and raises the powder-liquid ratio of the mixed mud to a preferable value in clinical operation. Even so, it is an object of the present invention to provide a curable liquid for biomaterials, which can secure the fluidity of the admixture that is preferable in clinical operation and is easy to use clinically, obtains a desired bending strength, and has a tenacity.
発明の要旨 この目的を達成するために、本発明は、リン酸カルシウ
ム系生体材料に使用する硬化液において、硬化液が、ク
エン酸及びDL−リンゴ酸の一方と、平均分子量24,000〜
28,800のアクリル酸イタコン酸共重合体を含み、硬化液
の粘度(動粘度)が900mm2/s以下であり、粉剤と混和し
たとき稠度が30以上になることを特徴とする生体材料用
硬化液を要旨としている。SUMMARY OF THE INVENTION In order to achieve this object, the present invention is a hardening liquid used for a calcium phosphate-based biomaterial, wherein the hardening liquid is one of citric acid and DL-malic acid, and an average molecular weight of 24,000 to.
A curing liquid for biomaterials, which contains 28,800 acrylic acid itaconic acid copolymers, has a viscosity (kinematic viscosity) of 900 mm 2 / s or less, and has a consistency of 30 or more when mixed with a powder. Is the gist.
実施例 本発明の硬化液は、リン酸カルシウム系生体材料の粉末
(粉剤)に用いる。この対象となるリン酸カルシウム系
生体材料としては、例えば、Ca10(PO4)6(OH)
2[合金ハイドロキシアパタイト:HAP]、非晶質リン酸
カルシウム〔Ca3(PO4)2・χH2O:χ=3〜4.5〕、α
−Ca3(PO4)2[アルファ型リン酸三カルシウム:αTC
P、β−Ca3(PO4)2[ベータ型リン酸三カルシウム:
βTCP]、CaHPO4・2H2O、CaHPO4、Ca8H2(PO4)6・5H2
O[リン酸八カルシウム:OCP]等がある。これらの生体
材料は、20〜50μm以下に粒度調整して微粉末とする
が、なかでもαTCPを使用するのが最も好ましい。Example The hardening liquid of this invention is used for the powder (powder) of a calcium-phosphate biomaterial. Examples of the calcium phosphate-based biomaterial targeted for this purpose include Ca 10 (PO 4 ) 6 (OH)
2 [alloy hydroxyapatite: HAP], amorphous calcium phosphate [Ca 3 (PO 4 ) 2 · χH 2 O: χ = 3 to 4.5], α
-Ca 3 (PO 4 ) 2 [alpha-type tricalcium phosphate: αTC
P, β-Ca 3 (PO 4 ) 2 [beta-type tricalcium phosphate:
βTCP], CaHPO 4 · 2H 2 O, CaHPO 4, Ca 8 H 2 (PO 4) 6 · 5H 2
O [octacalcium phosphate: OCP] and the like. The particle size of these biomaterials is adjusted to 20 to 50 μm or less to form a fine powder, and αTCP is most preferably used among them.
これらのリン酸カルシウム系生体材料は粉剤として単身
のまま用いても良く、2種〜数種の混和粉剤として用い
ても良い。These calcium phosphate-based biomaterials may be used alone as a powder, or may be used as a mixed powder of 2 to several types.
一方、これらのリン酸カルシウム系生体材料の単身また
は混合粉剤に更に追加物を添加しても良い。添加する追
加物としては、カルシウム化合物、アルミニウム化合
物、マグネシウム化合物、亜鉛化合物、珪素化合物、フ
ッ素化合物、ナトリウム化合物等があげられる。これら
は酸化物、水酸化物、リン酸塩、高次化合物等の化合物
として粉剤総量の0〜15重量%添加される。On the other hand, an additive may be further added to the single or mixed powder of these calcium phosphate-based biomaterials. Examples of the additive to be added include calcium compounds, aluminum compounds, magnesium compounds, zinc compounds, silicon compounds, fluorine compounds, sodium compounds and the like. These are added as compounds such as oxides, hydroxides, phosphates and higher order compounds in an amount of 0 to 15% by weight based on the total amount of powder.
添加の目的は、凝結硬化体の諸物性の向上を主目的と
し、生体に用いることを考慮して酸性度を調整する役割
もはたす。いずれにしても、これらの追加物は、硬化液
との硬化反応を著しく阻害するものであってはならない
ことから、例えば、酸化カルシウム、水酸化カルシウ
ム、酸化マグネシウム、酸化亜鉛、珪酸カルシウム、ク
エン酸カルシウム、リン酸ナトリウム、珪酸ジルコニウ
ム、酸化アルミニウム等をあげることができる。The main purpose of the addition is to improve the physical properties of the hardened setting material, and also to adjust the acidity in consideration of its use in living organisms. In any case, these additives should not significantly inhibit the curing reaction with the curing liquid, and therefore, for example, calcium oxide, calcium hydroxide, magnesium oxide, zinc oxide, calcium silicate, citric acid, etc. Examples thereof include calcium, sodium phosphate, zirconium silicate, aluminum oxide and the like.
本発明の硬化液は、硬化液の粘度が900mm2/s以下であ
る。この硬化液固有の粘性が極めて低いので、前記リン
酸カルシウム系生体材料に本発明の硬化液を使用する
と、この生体材料と硬化液との混和泥の流動性は従来の
混和泥のそれに比べて極めて優れている。The viscosity of the curable liquid of the present invention is 900 mm 2 / s or less. Since the viscosity inherent in this hardening liquid is extremely low, when the hardening liquid of the present invention is used for the calcium phosphate-based biomaterial, the fluidity of the mixed mud of this biomaterial and the hardening liquid is extremely superior to that of the conventional mixed mud. ing.
このため得られた混和泥の用途としては、混和泥の流動
性を積極的に利用して臨床療法において特に細く狭い狭
窄部、深在性窩洞等の充填に最適である。For this reason, the admixture obtained is most suitable for the filling of narrow narrow constrictions, deep cavities, etc. in clinical therapy by positively utilizing the fluidity of the admixture.
たとえば、得られた混和泥は、歯内療法分野において治
療により歯髄を除去された根部歯髄腔を充填する際に用
いる根管充填用シーラーあるいは糊材根管充填材として
の使用が好ましい。For example, the obtained mixed mud is preferably used as a root canal filling sealer or a paste root canal filling material used for filling the root pulp pulp cavity from which pulp has been removed by treatment in the endodontic field.
また、得られた混和泥の用途としては、歯科領域におい
て、たとえばエナメル質および象牙質欠損部を保存修復
する際に歯髄保護のためのベースとなる歯髄覆罩材ある
いは裏装用セメントとしての使用が好ましい。In addition, as an application of the obtained mixed mud, in the dental field, for example, as a pulp pulp covering material or a lining cement that serves as a base for pulp protection when conserving and repairing enamel and dentine defects, preferable.
硬化液の粘度が極めて低いので、混和泥の粉液比を上げ
ても、その稠度はその値が低くなりすぎることがなく臨
床操作上好ましい値にでき、かつ圧縮強さも高くでき
る。Since the viscosity of the hardening liquid is extremely low, even if the powder-liquid ratio of the mixed mud is increased, the value does not become too low, and the value can be made preferable for clinical operation, and the compression strength can be made high.
比較例1〜3と実施例4〜16 比較例1〜3と実施例4〜16を表−1に示す。Comparative Examples 1 to 3 and Examples 4 to 16 Tables 1 to 3 show Comparative Examples 1 to 3 and Examples 4 to 16.
ここで稠度とは、粉剤と液剤の混和後の流れを定荷重加
圧後の泥の広がりによる数値で表現したもので、混和泥
との流動性、取扱いやすさを示す尺度である。Here, the consistency is a numerical value of the flow of the powder and liquid after mixing, which is expressed by the spread of the mud after pressurizing under constant load, and is a measure showing the fluidity with the mixed mud and the ease of handling.
表1に示した実施例4〜16と比較例1〜3の粘度は、ガ
ラス管内流動式毛細管粘度計を用い、液温25±0.5℃に
て測定した。The viscosities of Examples 4 to 16 and Comparative Examples 1 to 3 shown in Table 1 were measured at a liquid temperature of 25 ± 0.5 ° C using a glass tube flow type capillary viscometer.
実施例4〜16と比較例1〜3における混和泥の稠度、硬
化時間、圧縮強さは、JIST−6602を準用して測定した。The consistency, setting time, and compressive strength of the mixed mud in Examples 4 to 16 and Comparative Examples 1 to 3 were measured by applying JIST-6602.
比較例1〜3の硬化液は、易水溶液カルボン酸もしくは
その誘導体を主成分とする水溶液からなる例であり、こ
れらの易水溶性カルボン酸もしくはその誘導体は、たと
えばギ酸、酢酸、アクリル酸、メタクリル酸等の脂肪酸
類、メリト酸等の炭素環カルボン酸類、シュウ酸、マロ
ン酸、コハク酸、グルタン酸、マレイン酸等のジカルボ
ン酸類、アコニット酸、トリカルバリル酸等のトリカル
ボン酸類、グリコール酸、乳酸、リンゴ酸、グリセリン
酸、酒石酸、クエン酸等のアルコール酸類等が挙げられ
るが、一般に、無毒な多塩基性低脂肪酸、なかんずくα
ヒドロキシカルボン酸が望ましく、水に対する溶解性の
難易度、混和泥の操作性、凝結硬化体の諸物性の点から
は、酸味料として食品添加物に認定されて生体に対する
安全性の高いクエン酸、DL−リンゴ酸等が好ましい。The curing liquids of Comparative Examples 1 to 3 are examples of an aqueous solution containing an easily aqueous carboxylic acid or its derivative as a main component, and these easily water-soluble carboxylic acids or their derivatives are, for example, formic acid, acetic acid, acrylic acid, and methacrylic acid. Fatty acids such as acids, carbocyclic carboxylic acids such as mellitic acid, dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, glutaric acid and maleic acid, tricarboxylic acids such as aconitic acid and tricarballylic acid, glycolic acid, lactic acid, Examples thereof include malic acid, glyceric acid, tartaric acid, alcoholic acids such as citric acid, and the like. Generally, non-toxic polybasic low fatty acids, especially α
Hydroxycarboxylic acid is desirable, citric acid, which is certified as a food additive as an acidulant and highly safe for living organisms, from the viewpoint of difficulty in solubility in water, operability of mixed mud, and various physical properties of a condensation hardening product, DL-malic acid and the like are preferred.
これらの易水溶性カルボン酸もしくはその誘導体は、粉
剤として単身のままの水溶液として用いても良く、2〜
数種の混和水溶液として用いても良い。These easily water-soluble carboxylic acids or their derivatives may be used as an aqueous solution as a powder as a powder,
You may use it as several types of mixed aqueous solution.
選択された所定量の易水溶性カルボン酸もしくはその誘
導体と、この主成分に必要に応じて追加成分あるいは添
加成分を加えて精製水とよく混和し、必要に応じて加熱
して溶解することにより硬化液を得ることができる。By adding a predetermined amount of the easily water-soluble carboxylic acid or its derivative and an additive component or an additive component to this main component, if necessary, and thoroughly mixing with purified water, and heating as necessary to dissolve A hardening liquid can be obtained.
これらの易水溶性カルボン酸もしくはその誘導体を好ま
しくは5〜65重量%含有させるが、それぞれの酸によっ
て溶解度が異なり、追加成分配合率による含有量の変化
または操作性、諸物性面からの至適濃度が存在するの
で、より好ましくは含有量が10〜50重量%となる。These easily water-soluble carboxylic acids or their derivatives are preferably contained in an amount of 5 to 65% by weight, but the solubilities differ depending on the respective acids, and the content changes depending on the blending ratio of additional components or the operability and various properties are optimal. Since the concentration exists, the content is more preferably 10 to 50% by weight.
易水溶液カルボン酸もしくは誘導体の含有量が5重量%
より少ない場合、硬化時間が遅くなり、強度が充分でな
い。Aqueous solution Carboxylic acid or derivative content 5% by weight
If it is less, the curing time will be delayed and the strength will not be sufficient.
また、易水溶性カルボン酸もしくは誘導体の含有量が65
重量%より多い場合、硬化時間が早くなりすぎ、粘稠性
が増大して操作しにくい。そして酸性度が高まる(pHが
低すぎて刺激性が出る)。In addition, the content of easily water-soluble carboxylic acid or derivative is 65
If it is more than wt%, the curing time will be too fast and the viscosity will increase, making it difficult to operate. Then the acidity increases (pH is too low and irritation occurs).
実施例4〜16の硬化液は、易水溶性カルボン酸もしくは
その誘導体の不飽和カルボン酸共重合体のを主成分とす
る水溶液からなる。The curing liquids of Examples 4 to 16 consisted of aqueous solutions containing an unsaturated carboxylic acid copolymer of a water-soluble carboxylic acid or its derivative as a main component.
不飽和カルボン酸共重合体は、液粘性調整剤として効果
的に作用するが、諸物性面においても改善することがで
きるもので圧縮強さを増強改善させる。The unsaturated carboxylic acid copolymer acts effectively as a liquid viscosity modifier, but it can also improve various physical properties, and enhances and improves the compressive strength.
選択された所定量の易水溶性カルボン酸もしくはその誘
導体と不飽和カルボン酸共重合体を主成分とし、この主
成分に必要に応じて追加成分あるいは添加成分を加えて
精製水とよく混合し、必要に応じて加熱して溶解するこ
とにより硬化液を得ることができる。A main component is a predetermined amount of a water-soluble carboxylic acid or its derivative and an unsaturated carboxylic acid copolymer selected, and if necessary, an additional component or an additional component is added to the main component and well mixed with purified water, A hardening liquid can be obtained by heating and melt | dissolving as needed.
易水溶性カルボン酸もしくは誘導体と、不飽和カルボン
酸共重合体の総含有量が好ましくは5〜65重量%であ
る。The total content of the readily water-soluble carboxylic acid or derivative and the unsaturated carboxylic acid copolymer is preferably 5 to 65% by weight.
この総含有量が5重量%より少ない場合、硬化時間が遅
くなり、強度が充分でない。If the total content is less than 5% by weight, the curing time will be delayed and the strength will be insufficient.
また、総含有量が65重量%より多い場合、硬化時間が早
くなりすぎ粘稠性が増大して操作しくい。そして酸性度
が高まる(pHが低すぎで刺激性がでる)。On the other hand, if the total content is more than 65% by weight, the curing time will be too fast and the viscosity will increase, making operation difficult. And the acidity increases (pH is too low and irritation occurs).
また、この不飽和カルボン酸共重合体を多量に追加する
と、従来のポリアクリル酸系硬化液と同様のものとなっ
てしまい、液粘性が上昇し、混和泥の扱いが困難にな
る。従って含有量は、硬化液総量の25重量%以下で良
く、特に5〜15重量%程度が最も好ましい。Further, if a large amount of this unsaturated carboxylic acid copolymer is added, it becomes the same as the conventional polyacrylic acid-based curing liquid, the liquid viscosity increases, and handling of the mixed mud becomes difficult. Therefore, the content may be 25% by weight or less based on the total amount of the curing liquid, and most preferably about 5 to 15% by weight.
この追加配合量が25重量%より多い場合、液粘性が高ま
り、混和泥の稠度が上がり、流動性が悪くなる。If this additional compounding amount is more than 25% by weight, the liquid viscosity increases, the consistency of the mixed mud increases, and the fluidity deteriorates.
不飽和カルボン酸共重合体としては、たとえば、イタコ
ン酸とアクリル酸と共重合体、フマル酸とアクリル酸の
共重合体、マレイン酸とアルリル酸の共重合体などがあ
る。Examples of the unsaturated carboxylic acid copolymer include a copolymer of itaconic acid and acrylic acid, a copolymer of fumaric acid and acrylic acid, and a copolymer of maleic acid and allyl acid.
実施例1〜16および比較例1〜3のアクリル酸イタコン
酸共重合体は、平均分子量が24,000〜28,800のものであ
る。The acrylic acid itaconic acid copolymers of Examples 1 to 16 and Comparative Examples 1 to 3 have an average molecular weight of 24,000 to 28,800.
ところで、比較例3と実施例5〜16は、他の少量追加成
分を含んでいる。追加成分は、混和泥および凝結硬化体
のより一層の操作性の改善、諸物性の向上、生体に対す
る刺激性、為害性の緩和等の目的で、キレート化剤、PH
調整剤、アミノ酸類、無機酸等が随時添加される。By the way, Comparative Example 3 and Examples 5 to 16 contain other minor addition components. The additional component is a chelating agent, PH for the purpose of further improving the operability of the mixed mud and the setting and hardening body, improving various physical properties, irritating to the living body, and mitigating harmful effects.
Regulators, amino acids, inorganic acids, etc. are added at any time.
これらと例としてたとえば、、ニトリロ三酢酸[NT
A]、NTA−2Na、NTA−3Na、エチレンジアミン四酢酸[E
DTA−4H]、EDTA−4Na、Ca(OH)2、Mg(OH)2、Al
(OH)3、NaOH、グリシン、アスパラギン酸、グルタミ
ン酸、正リン酸、塩酸、硝酸、Na2HPO4等が挙げられ
る。これらは硬化液の総重量に対して0〜10重量%程度
添加される。For example, nitrilotriacetic acid [NT
A], NTA-2Na, NTA-3Na, ethylenediaminetetraacetic acid [E
DTA-4H], EDTA-4Na, Ca (OH) 2 , Mg (OH) 2 , Al
(OH) 3 , NaOH, glycine, aspartic acid, glutamic acid, orthophosphoric acid, hydrochloric acid, nitric acid, Na 2 HPO 4 and the like. These are added in an amount of about 0 to 10% by weight based on the total weight of the curing liquid.
比較例1〜3と、実施例4〜6、9〜11、13〜15は、リ
ン酸カルシウム系生体材料のαTCPを粉剤として用い混
和泥にする。実施例7、8、12、16は、αTCPに珪酸カ
ルシウムを5重量%添加したものを粉剤として用い混和
泥にする。得られた各混和泥は生体への刺激性および毒
性がない。また混和泥の状態はパサパサしない。比較例
1〜3の実施例4〜16の硬化液は、硬化液の粘度が従来
のポリアクリル酸系硬化液のそれに比べて低くできてい
るので、混和泥の流動性を優れたものにすることができ
る。In Comparative Examples 1 to 3 and Examples 4 to 6, 9 to 11 and 13 to 15, αTCP, which is a calcium phosphate-based biomaterial, is used as a dusting agent to form an admixture. In Examples 7, 8, 12, and 16, a mixture of αTCP and 5% by weight of calcium silicate is used as a dusting agent to prepare a mixed mud. The obtained mixed mud is neither irritating nor toxic to living organisms. Also, the state of the mixed mud is not dry. The curable liquids of Examples 4 to 16 of Comparative Examples 1 to 3 have a lower viscosity than that of the conventional polyacrylic acid-based curable liquids, and therefore have excellent fluidity of the mixed mud. be able to.
また、混和泥の稠度を好ましい値に確保しながら、αTC
Pまたは追加成分の添加されたαTCPと各実施例の硬化液
との粉液比を上げることができ、凝結硬化体は短時間で
より強い圧縮強さを得られる。In addition, while ensuring the consistency of the mixed mud to a desirable value, αTC
It is possible to increase the powder-liquid ratio of P or the αTCP to which the additional component is added and the hardening liquid of each example, and the setting hardening product can obtain stronger compressive strength in a short time.
表−2は従来の比較例17、18を示している。粉剤はαTC
Pを用いた。各比較例はともに硬化液の粘度が少なくと
も1000mm2/s以上で、混和泥の粉液比は本発明の実施例
の粉液比に比べて低く稠度も低い。Table-2 shows the conventional comparative examples 17 and 18. Dust is αTC
P was used. In each of the comparative examples, the viscosity of the hardening liquid is at least 1000 mm 2 / s or more, and the powder-liquid ratio of the mixed mud is lower than that of the examples of the present invention, and the consistency is low.
発明の効果 本発明によれば、従来に比べて硬化液固有の液粘性(硬
化液の粘度)を下げているので、リン酸カルシウム系生
体材料と本発明の硬化液から成る混和泥の粉液比を臨床
操作上好ましい値まで上げても臨床操作上好ましい混和
泥の流動性を確保できる。EFFECTS OF THE INVENTION According to the present invention, the liquid viscosity peculiar to the hardening liquid (viscosity of the hardening liquid) is lowered as compared with the conventional one, so that the powder-liquid ratio of the mixed mud composed of the calcium phosphate biomaterial and the hardening liquid of the present invention can be reduced. Even if the value is increased to a value preferable for clinical operation, the fluidity of the admixture that is preferable for clinical operation can be secured.
したがって、従来操作性を重視する臨床分野(特に歯内
治療法分野や保存修復分野)では、リン酸カルシウム系
の生体材料の臨床操作が容易となる。Therefore, in the clinical field (especially in the endodontic therapy field and the preservation / restoration field) where the conventional operability is important, the clinical operation of the calcium phosphate-based biomaterial becomes easy.
また、平均分子量24,000〜28,800のアクリル酸イタコン
酸共重合体を使用し、それをクエン酸又はDL−リンゴ酸
に組み合わせて使用するため、曲げ強度が良好となり、
もろさの点で優れている。Further, using an acrylic acid itaconic acid copolymer having an average molecular weight of 24,000 to 28,800 and using it in combination with citric acid or DL-malic acid, the bending strength becomes good,
Excellent in fragility.
Claims (1)
化液において、硬化液が、クエン酸及びDL−リンゴ酸の
一方と、平均分子量24,000〜28,800のアクリル酸イタコ
ン酸共重合体を含み、硬化液の粘度(動粘度)が900mm2
/s以下であり、粉剤と混和したとき稠度が30以上になる
ことを特徴とする生体材料用硬化液。1. A curing liquid for use in a calcium phosphate-based biomaterial, wherein the curing liquid contains one of citric acid and DL-malic acid and an acrylic acid itaconic acid copolymer having an average molecular weight of 24,000 to 28,800. Viscosity (kinematic viscosity) 900 mm 2
/ s or less and a consistency of 30 or more when mixed with a powder, and a hardening liquid for biomaterials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61058133A JPH0793942B2 (en) | 1986-03-18 | 1986-03-18 | Curing liquid for biomaterials |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61058133A JPH0793942B2 (en) | 1986-03-18 | 1986-03-18 | Curing liquid for biomaterials |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62217969A JPS62217969A (en) | 1987-09-25 |
| JPH0793942B2 true JPH0793942B2 (en) | 1995-10-11 |
Family
ID=13075483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61058133A Expired - Fee Related JPH0793942B2 (en) | 1986-03-18 | 1986-03-18 | Curing liquid for biomaterials |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0793942B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62230708A (en) * | 1986-03-31 | 1987-10-09 | Sangi:Kk | Calcium phosphate composition |
| JPH0657243B2 (en) * | 1986-12-16 | 1994-08-03 | 大日本塗料株式会社 | Medical or dental curable composition |
| JP2548745B2 (en) * | 1987-10-15 | 1996-10-30 | 住友大阪セメント株式会社 | Bone cement composition |
| JP2774987B2 (en) * | 1988-08-10 | 1998-07-09 | 新田ゼラチン 株式会社 | Medical and dental curable materials |
| JPH0645493B2 (en) * | 1990-05-09 | 1994-06-15 | 三菱マテリアル株式会社 | Hydraulic calcium phosphate cement composition |
| JPH0645494B2 (en) * | 1990-05-09 | 1994-06-15 | 三菱マテリアル株式会社 | Hydraulic calcium phosphate cement composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60225568A (en) * | 1984-04-24 | 1985-11-09 | 株式会社アドバンス | Living body hard tissue repairing material |
| JPS61272056A (en) * | 1985-05-25 | 1986-12-02 | 株式会社 はいる | Curable composition |
| JPS6212705A (en) * | 1985-07-10 | 1987-01-21 | Meishin Kk | Medical or dental cement composition |
| JPH0793941B2 (en) * | 1986-03-12 | 1995-10-11 | 三金工業株式会社 | Manufacturing method of biological hard tissue repair material |
-
1986
- 1986-03-18 JP JP61058133A patent/JPH0793942B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62217969A (en) | 1987-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4900697A (en) | Glass powders for dental glass ionomer cements | |
| US4677140A (en) | Surgical cement containing α-tricalcium phosphate, poly(carboxylic acid) and water | |
| JP4132806B2 (en) | Dental paste glass ionomer cement composition | |
| US6291548B1 (en) | Dental cement composition | |
| JP4215884B2 (en) | Calcium phosphate cement and calcium phosphate cement composition | |
| JP2008519749A (en) | Dental glass composition | |
| JPH05168692A (en) | Curable material for restoration of hard biotissue | |
| JPH0793942B2 (en) | Curing liquid for biomaterials | |
| JP2021054812A (en) | Dental glass ionomer cement composition | |
| JPS6283348A (en) | Curable composition for medical use | |
| JPS6219508A (en) | Root canal filling material for dental use | |
| JPH10248915A (en) | Calcium phosphate cement hardening liquid and composition for hardened calcium phosphate cement | |
| CN110302062A (en) | Glass ionomer cement composition for dental bonding with good removability | |
| JPH0793941B2 (en) | Manufacturing method of biological hard tissue repair material | |
| WO2013135370A1 (en) | Bioactive hydraulic organic matrix materials | |
| JPS62153204A (en) | Root canal filling material for dental use | |
| JPH0248479A (en) | Method for curing curable composition | |
| JP2780120B2 (en) | Hardening calcium phosphate dental composition | |
| JP6501189B2 (en) | Dental curable composition and method for producing the same | |
| JP7061189B2 (en) | Dental fluoroaluminosilicate glass powder | |
| JPS62277966A (en) | Living body hard tissue repairing material | |
| JPS61236644A (en) | Calcium phosphate hardenable composition | |
| JP4319280B2 (en) | Calcium phosphate cement powder and calcium phosphate cement composition | |
| JPS6323671A (en) | Medical curable composition | |
| JPH0763502B2 (en) | Human hard tissue replacement composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |